Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Comparison of Temporal Bone Parameters before Cochlear Implantation in Patients with and without Facial Nerve Stimulation.

Kasetty VM, Zimmerman Z, King S, Seyyedi M.

J Audiol Otol. 2019 Oct;23(4):193-196. doi: 10.7874/jao.2019.00129. Epub 2019 Sep 24.

2.

PIP2 Reshapes Membranes through Asymmetric Desorption.

Shukla S, Jin R, Robustelli J, Zimmerman ZE, Baumgart T.

Biophys J. 2019 Sep 3;117(5):962-974. doi: 10.1016/j.bpj.2019.07.047. Epub 2019 Aug 5.

PMID:
31445680
3.

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, Topp MS.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1498-1504. doi: 10.1016/j.bbmt.2019.04.010. Epub 2019 Apr 17.

4.

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.

Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H.

Leuk Lymphoma. 2019 Sep;60(9):2214-2222. doi: 10.1080/10428194.2019.1576872. Epub 2019 Apr 5.

PMID:
30947585
5.

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S.

Adv Ther. 2019 Apr;36(4):950-961. doi: 10.1007/s12325-019-0873-7. Epub 2019 Feb 13.

PMID:
30758745
6.

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.

Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, Zimmerman Z, Topp MS.

Ann Hematol. 2019 Jan;98(1):159-167. doi: 10.1007/s00277-018-3497-0. Epub 2018 Sep 20.

7.

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.

Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, Zimmerman Z, Kormany W, Topp MS.

Blood Adv. 2018 Jul 10;2(13):1522-1531. doi: 10.1182/bloodadvances.2018019034.

8.

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.

Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC.

Blood. 2018 Jun 28;131(26):2906-2914. doi: 10.1182/blood-2017-09-804658. Epub 2018 May 8.

9.

Basal cell adenocarcinoma of the skull base: A diagnostic challenge.

Zimmerman ZA, Shapiro J, Arturo Solares C, Biddinger P, Byrd JK.

Oral Oncol. 2017 Sep;72:192-193. doi: 10.1016/j.oraloncology.2017.07.008. Epub 2017 Jul 23. No abstract available.

PMID:
28743467
10.

Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.

Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A.

J Med Econ. 2017 Sep;20(9):911-922. doi: 10.1080/13696998.2017.1344127. Epub 2017 Jul 11.

PMID:
28631497
11.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

12.

Correction regarding data on blinatumomab-associated seizures.

Topp MS, Zimmerman Z, Kantarjian HM.

Nat Rev Clin Oncol. 2016 Oct;13(10):650. doi: 10.1038/nrclinonc.2016.133. Epub 2016 Aug 23. No abstract available.

PMID:
27550855
13.

Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.

Zimmerman Z, Maniar T, Nagorsen D.

Int Immunol. 2015 Jan;27(1):31-7. doi: 10.1093/intimm/dxu089. Epub 2014 Sep 19. Review.

PMID:
25239133
14.

Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail.

Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT, Chien AJ.

PLoS One. 2013 Jul 15;8(7):e69593. doi: 10.1371/journal.pone.0069593. Print 2013.

15.

Targeting Wnt pathways in disease.

Zimmerman ZF, Moon RT, Chien AJ.

Cold Spring Harb Perspect Biol. 2012 Nov 1;4(11). pii: a008086. doi: 10.1101/cshperspect.a008086. Review.

16.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.

Zimmerman Z, Scott BL, Gopal AK, Sandmaier BM, Maloney DG, Deeg HJ.

Bone Marrow Transplant. 2012 Jun;47(6):804-9. doi: 10.1038/bmt.2011.180. Epub 2011 Sep 12.

17.

Comparison of frozen versus desiccated reference human red blood cells for hemagglutination assays.

Ho D, Schierts J, Zimmerman Z, Gadsden I, Bruttig S.

Transfusion. 2009 Oct;49(10):2173-80. doi: 10.1111/j.1537-2995.2009.02270.x. Epub 2009 Jun 23.

PMID:
19555416
18.
19.

Cytolytic pathways used by effector cells derived from recipient naive and memory T cells and natural killer cells in resistance to allogeneic hematopoietic cell transplantation.

Zimmerman Z, Jones M, Shatry A, Komatsu M, Mammolenti M, Levy R.

Biol Blood Marrow Transplant. 2005 Dec;11(12):957-71. Review. No abstract available.

21.

Investing in Oregon's expanded food and nutrition education program (EFNEP): documenting costs and benefits.

Schuster E, Zimmerman ZL, Engle M, Smiley J, Syversen E, Murray J.

J Nutr Educ Behav. 2003 Jul-Aug;35(4):200-6.

PMID:
12859884
22.

Disruption of centrosome structure, chromosome segregation, and cytokinesis by misexpression of human Cdc14A phosphatase.

Kaiser BK, Zimmerman ZA, Charbonneau H, Jackson PK.

Mol Biol Cell. 2002 Jul;13(7):2289-300.

23.

The Sda1 protein is required for passage through start.

Zimmerman ZA, Kellogg DR.

Mol Biol Cell. 2001 Jan;12(1):201-19.

24.

Thick-walled physical models improve estimates of operative temperatures for moderate to large-sized reptiles.

O'Connor MP, Zimmerman ZL, Dzialowski DE, Spotila SJ.

J Therm Biol. 2000 Aug 1;25(4):293-304. No abstract available.

PMID:
10745126
25.

Supplemental Content

Loading ...
Support Center